Clinical Trial Update: CURATE.AI Optimized Modulation for Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for CURATE.AI optimized modulation in multiple myeloma across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CURATE.AI optimized modulation

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: UNKNOWN